Showing results (191-200 of 438) with videos related to

Sort By:
Pageof 44
British Journal of Cancer|February 9, 2023
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' developmentRoberto Moretto, Marco Maria Germani, Mirella Giordano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2023
ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction AdenocarcinomaSamuel J Klempner, Keun-Wook Lee, Kohei Shitara, et al.
JCO Precision Oncology|October 5, 2023
Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or ChemotherapyRoberto Moretto, Marco Maria Germani, Javier Ros, et al.
British Journal of Cancer|October 7, 2020
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONODaniele Rossini, Sara Lonardi, Carlotta Antoniotti, et al.
Frontiers in Oncology|December 29, 2022
Case report: Complete pathologic response with first-line immunotherapy combination in a young adult with massive liver dissemination of mismatch repair-deficient metastatic colorectal cancer: Immunological and molecular profilingFrancesca Bergamo, Silvia Dalla Santa, Fotios Loupakis, et al.
JCO Precision Oncology|April 18, 2025
Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal CancerRoberto Moretto, Marco Maria Germani, Martina Carullo, et al.
Journal of Neuro-Oncology|October 15, 2025
Incidence and survival of adult central nervous system tumors in the Veneto region: a population-based registry study (2016-2020)Alessandra Andreotti, Eliana Ferroni, Stefano Guzzinati, et al.
Journal for Immunotherapy of Cancer|January 4, 2025
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitorsJulien Taieb, Margherita Ambrosini, Emily Alouani, et al.
Therapeutic Advances in Medical Oncology|January 8, 2025
Prognostic impact of depth of response and early tumour shrinkage in patients with BRAF -mutated metastatic colorectal cancer treated with targeted therapyGuglielmo Vetere, Marco Maria Germani, Carlotta Antoniotti, et al.
Plos One|July 18, 2013
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumabFotios Loupakis, Chiara Cremolini, Dongyun Yang, et al.
Pageof 44